Literature DB >> 11562440

Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors.

D J Fischer1, N Nusser, T Virag, K Yokoyama, D L Baker, D Bautista, A L Parrill, G Tigyi.   

Abstract

Lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are members of the phospholipid growth factor family. A major limitation in the field to date has been a lack of receptor subtype-specific agonists and antagonists. Here, we report that dioctylglycerol pyrophosphate and dioctylphosphatidic acid are selective antagonists of the LPA(1) and LPA(3) receptors, but prefer LPA(3) by an order of magnitude. Neither molecule had an agonistic or antagonistic effect on LPA(2) receptor. Consistent with this receptor subtype selectivity, dioctylglycerol pyrophosphate inhibited cellular responses to LPA in NIH3T3 fibroblasts, HEY ovarian cancer cells, PC12 pheochromocytoma cells, and Xenopus laevis oocytes. Responses elicited by S1P in these cell lines that endogenously express S1P(1), S1P(2), S1P(3), and S1P(5) receptors were unaffected by dioctylglycerol pyrophosphate. Responses evoked by the G protein-coupled receptor ligands acetylcholine, serotonin, ATP, and thrombin receptor-activating peptide were similarly unaffected, suggesting that the short-chain phosphatidates are receptor subtype-specific lysophosphatidate antagonists.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562440

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  33 in total

Review 1.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 2.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

3.  Phosphatidic acid drives mTORC1 lysosomal translocation in the absence of amino acids.

Authors:  Maria A Frias; Suman Mukhopadhyay; Elyssa Lehman; Aleksandra Walasek; Matthew Utter; Deepak Menon; David A Foster
Journal:  J Biol Chem       Date:  2019-11-24       Impact factor: 5.157

4.  2D binary QSAR modeling of LPA3 receptor antagonism.

Authors:  James I Fells; Ryoko Tsukahara; Jianxiong Liu; Gabor Tigyi; Abby L Parrill
Journal:  J Mol Graph Model       Date:  2010-03-07       Impact factor: 2.518

5.  Identification of non-lipid LPA3 antagonists by virtual screening.

Authors:  James I Fells; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; Donna H Perygin; Daniel A Osborne; Gabor Tigyi; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2008-04-18       Impact factor: 3.641

6.  Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect.

Authors:  Mee-Sup Yoon; Yuting Sun; Edwin Arauz; Yu Jiang; Jie Chen
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

7.  LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction.

Authors:  Péter Tibor Dancs; Éva Ruisanchez; Andrea Balogh; Cecília Rita Panta; Zsuzsanna Miklós; Rolf M Nüsing; Junken Aoki; Jerold Chun; Stefan Offermanns; Gábor Tigyi; Zoltán Benyó
Journal:  FASEB J       Date:  2017-01-09       Impact factor: 5.191

Review 8.  Lysophosphatidic acid (LPA) signaling in vertebrate reproduction.

Authors:  Xiaoqin Ye; Jerold Chun
Journal:  Trends Endocrinol Metab       Date:  2010-01       Impact factor: 12.015

Review 9.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

10.  Receptor-mediated vascular smooth muscle migration induced by LPA involves p38 mitogen-activated protein kinase pathway activation.

Authors:  Zhi-Bin Zhou; Jian-Ping Niu; Zhi-Jun Zhang
Journal:  Int J Mol Sci       Date:  2009-07-13       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.